GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | App | multiple interactions | EXP | | 6480464 | CTD | [1,2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of APP mRNA; [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of APP mRNA; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in decreased expression of BAD protein modified form]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in decreased expression of BCL2 protein]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in decreased expression of BCL2L1 protein]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in decreased expression of IGF1R protein modified form]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in decreased expression of SIRT1 protein]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in decreased expression of SOD2 protein]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in increased expression of CASP12 protein modified form]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in increased expression of CASP3 protein modified form]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in increased expression of CASP9 protein modified form]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in increased expression of CYCS protein]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in increased expression of FADD protein]; Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in increased expression of FAS protein] | PMID:20938992 PMID:22206623 PMID:29068127 | App | decreases expression | ISO | APP (Homo sapiens) | 6480464 | CTD | Folic Acid results in decreased expression of APP protein | PMID:26492244 | App | multiple interactions | ISO | APP (Homo sapiens) | 6480464 | CTD | APP protein affects the reaction [Folic Acid affects the expression of DNMT1 mRNA]; APP protein affects the reaction [Folic Acid affects the expression of DNMT3B mRNA]; APP protein affects the reaction [Folic Acid affects the expression of DNMT3B protein]; pyrimidin-2-one beta-ribofuranoside inhibits the reaction [Folic Acid results in decreased expression of APP protein] | PMID:26492244 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |